Literature DB >> 1155479

Penetration of antimicrobial agents into bronchial secretions.

G A Wong, T H Pierce, E Goldstein, P D Hoeprich.   

Abstract

The entry of ampicillin, cephalothin and gentamicin into traceobronchopulmonary secretions/exudates was assessed in 22 patients during 28, episodes of pneumonia or bronchitis. Specimens were collected from the lower respiratory tract via tracheostomies or endotracheal tubes using either the flexible fiberoptic bronchoscope (50 specimens) or an intratracheal catheter (59 specimens). Venous blood was obtained at the same time. The concentrations in the bronchial specimens were less than those in the corresponding serums, amounting to about 10 per cent with ampicillin, 25 per cent with cephalothin and equal to or greater than 40 per cent with gentamicin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155479     DOI: 10.1016/0002-9343(75)90356-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Aminoglycoside therapy: current and prospective uses.

Authors:  J E Leggett
Journal:  Tex Heart Inst J       Date:  1990

3.  Cefuroxime: pharmacokinetic study in bronchial secretions.

Authors:  E Bergogne-Berezin; P Even; G Berthelot; J Pierre
Journal:  Proc R Soc Med       Date:  1977

4.  Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.

Authors:  Y J Valcke; M T Rosseel; R A Pauwels; M G Bogaert; M E Van der Straeten
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 5.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

6.  Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.

Authors:  R J Wallace; S L Niefield; S Waters; B Waters; R J Awe; K Wiss; R R Martin; S B Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

7.  Ceforanide (BL-S786) in the treatment of community-acquired bacterial pneumonia.

Authors:  R J Wallace; R R Martin; S B Greenberg
Journal:  Infection       Date:  1979       Impact factor: 3.553

8.  Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.

Authors:  G Mombelli; L Coppens; J P Thys; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

9.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

Review 10.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.